Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
Lisa V E Oostenbrink, Cornelia M Jol-van der Zijde, Katrine Kielsen, Anja M Jansen-Hoogendijk, Marianne Ifversen, Klaus G Müller, Arjan C Lankester, Astrid G S van Halteren, Robbert G M Bredius, Marco W Schilham, Maarten J D van Tol, Lisa V E Oostenbrink, Cornelia M Jol-van der Zijde, Katrine Kielsen, Anja M Jansen-Hoogendijk, Marianne Ifversen, Klaus G Müller, Arjan C Lankester, Astrid G S van Halteren, Robbert G M Bredius, Marco W Schilham, Maarten J D van Tol
Abstract
Anti-thymocyte globulin (ATG) is a lymphocyte depleting agent applied in hematopoietic stem cell transplantation (HSCT) to prevent rejection and Graft-vs.-Host Disease (GvHD). In this study, we compared two rabbit ATG products, ATG-Genzyme (ATG-GENZ), and ATG-Fresenius (ATG-FRES), with respect to dosing, clearance of the active lymphocyte binding component, post-HSCT immune reconstitution and clinical outcome. Fifty-eigth pediatric acute leukemia patients (n = 42 ATG-GENZ, n = 16 ATG-FRES), who received a non-depleted bone marrow or peripheral blood stem cell graft from an unrelated donor were included. ATG-GENZ was given at a dosage of 6-10 mg/kg; ATG-FRES at 45-60 mg/kg. The active component of ATG from both products was cleared at different rates. Within the ATG-FRES dose range no differences were found in clearance of active ATG or T-cell re-appearance. However, the high dosage of ATG-GENZ (10 mg/kg), in contrast to the low dosage (6-8 mg/kg), correlated with prolonged persistence of active ATG and delayed T-cell reconstitution. Occurrence of serious acute GvHD (grade III-IV) was highest in the ATG-GENZ-low dosage group. These results imply that dosing of ATG-GENZ is more critical than dosing of ATG-FRES due to the difference in clearance of active ATG. This should be taken into account when designing clinical protocols.
Keywords: ATG; Fresenius; Genzyme; acute GvHD; pediatrics; serotherapy.
Figures
References
- Zand M. B-cell activity of polyclonal antithymocyte globulins. Transplantation. (2006) 82:1387–95. 10.1097/01.tp.0000244063.05338.27
- Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P, et al. . Immune reconstitution after anti- thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy. (2012) 14:1258–75. 10.3109/14653249.2012.715243
- Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. (2007) 21:1387–94. 10.1038/sj.leu.2404683
- Penack O, Fischer L, Gentilini C. The type of ATG matters—natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol. (2007) 18:85–7. 10.1016/j.trim.2007.05.001
- Popow I, Leitner J, Grabmeier-Pfistershammer K, Majdic O, Zlabinger GJ, Kundi M, et al. . A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J Transplant. (2013) 13:3103–13. 10.1111/ajt.12514
- Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, et al. . Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia working party of the european society for blood and marrow transplantation. Haematologica. (2017) 102:224–34. 10.3324/haematol.2016.148510
- Seidel MG, Fritsch G, Matthes-martin S, Lawitschka A, Lion T, Po U, et al. . Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. (2005) 27:532–6. 10.1097/01.mph.0000184575.00717.25
- Call S, Kasow K, Barfield R. Total and active rabbit antithymocyte globulin (rATG; thymoglobulin®) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. (2009) 15:274–8. 10.1016/j.bbmt.2008.11.027
- Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TCG, et al. . Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. (2015) 2:e194–203. 10.1016/S2352-3026(15)00045-9
- Mensen A, Na IK, Häfer R, Meerbach A, Schlecht M, Pietschmann ML, et al. . Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD. J Cancer Res Clin Oncol. (2014) 140:1971–80. 10.1007/s00432-014-1742-z
- Ayuk F, Maywald N, Hannemann S, Larsen U, Zander A, Kröger N. Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies. Anticancer Res. (2009) 29:1355–60.
- Popow I, Leitner J, Majdic O, Kovarik JJ, Saemann MD, Zlabinger GJ, Steinberger P. Assessment of batch to batch variation in polyclonal antithymocyte globulin preparations. Transplantation. (2012) 93:32–40. 10.1097/TP.0b013e31823bb664
- Regan JF, Lyonnais C, Campbell K, Smith LV, Buelow R. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol. (2001) 9:29–36. 10.1016/S0966-3274(01)00048-X
- Kakhniashvili I, Filicko J, Kraft WK, Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. (2005) 11:609–18. 10.1016/j.bbmt.2005.05.001
- Waller E, Langston A, Lonial S. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. (2003) 9:460–71. 10.1016/S1083-8791(03)00127-7
- Eiermann TH, Freitag S, Cortes-dericks L. Jurkat cell-reactive anti-thymocyte globulin assessed ex vivo by flow cytometry persists three weeks in scirculation. J Hematother Stem Cell Res. (2001) 390:385–90. 10.1089/152581601750288984
- Polverelli N, Malagola M, Turra A, Skert C, Perucca S, Chiarini M, et al. Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years. Leuk Lymphoma. (2018) 12:1–6. 10.1080/10428194.2018.1439584
- Huang W, Zhao X, Tian Y, Cao T, Li Y, Liu Z, et al. . Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-thymoglobulin versus ATG-Fresenius: a single-center study. Med Oncol. (2015) 32:465. 10.1007/s12032-014-0465-y
- Terasako K, Sato K, Sato M, Kimura S, Nakasone H, Okuda S, et al. . The effect of different ATG preparations on immune recovery after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia. Hematology. (2010) 15:165–9. 10.1179/102453309X12583347113852
- Cicora F, Mos F, Paz M, Roberti J. Clinical experience with thymoglobulin and antithymocyte globulin-fresenius as induction therapy in renal transplant patients: a retrospective study. Exp Clin Transplant. (2013) 11:418–22. 10.6002/ect.2013.0027
- Burkhalter F, Schaub S, Bucher C, Gürke L, Bachmann A, Hopfer H, et al. . A comparison of two types of rabbit antithymocyte globulin induction therapy in immunological high-risk kidney recipients: a prospective randomized control study. PLoS ONE. (2016) 11:e0165233. 10.1371/journal.pone.0165233
- Gharekhani A, Entezari-maleki T, Dashti-khavidaki S, Khalili H. Expert opinion on biological therapy a review on comparing two commonly used rabbit anti-thymocyte globulins as induction therapy in solid organ transplantation. Expert opin Biol Ther. (2013) 13:1299-313. 10.1517/14712598.2013.822064
- Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluijs AB, Nierkens S, et al. . Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood. (2016) 128:2734–41. 10.1182/blood-2016-06-721936
- Büchler M, Longuet H, Lemoine R, Herr F, Gatault P, Thibault G, et al. . Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. Transpl Immunol. (2013) 28:120–6. 10.1016/j.trim.2013.03.001
- Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, et al. . Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma. (2012) 53:915–9. 10.3109/10428194.2011.634039
- Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol MJD, Bartelink IH, Bredius RGM, et al. . Population pharmacokinetic modeling of thymoglobulin®in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing. Clin Pharmacokinet. (2015) 54:435-46. 10.1007/s40262-014-0214-6
- Locatelli F, Bernardo ME, Bertaina A, Rognoni C, Comoli P, Rovelli A, et al. . Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. (2017) 18:1126–36. 10.1016/S1470-2045(17)30417-5
- Willemsen L, Jol-van der Zijde CM, Admiraal R, Putter H, Jansen-Hoogendijk AM, Ostaijen-ten Dam MM, et al. . Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. Biol Blood Marrow Transplant. (2015) 21:473–82. 10.1016/j.bbmt.2014.11.674
- Jol-van der Zijde CM, Bredius RGM, Jansen-Hoogendijk AM, Raaijmakers S, Egeler RM, Lankester AC, et al. . IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD. Bone Marrow Transplant. (2012) 47:360–8. 10.1038/bmt.2011.166
- Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. (1974) 18:295–304. 10.1097/00007890-197410000-00001
- Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, et al. . NIH consensus development project on criteria for clinical trials in chronic graft-versus-Host Disease: II. The 2014 pathology working group report. Biol Blood Marrow Transplant. (2015) 21:589–603. 10.1016/j.bbmt.2014.12.031
- Claas ECJ, Schilham MW, de Brouwer CS, Hubacek P, Echavarria M, Lankester AC, et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J Clin Microbiol. (2005) 43:1738–44. 10.1128/JCM.43.4.1738-1744.2005
- Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol. (2000) 38:712–5.
- Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol M, Bartelink I, Bredius R, et al. Population pharmacokinetic modeling of thymoglobulin in children receiving allogeneic-hematopoietic cell transplantation (HCT): towards individualized dosing to improve survival. Biol Blood Marrow Transplant. (2014) 20:S96–8. 10.1016/j.bbmt.2013.12.129
- Podgorny P, Ugarte-Torres A. high rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative. Biol Blood Marrow Transplant. (2010) 16:915–26. 10.1016/j.bbmt.2010.02.027
- Chawla S, Dharmani-Khan P, Liu Y, Prokopishyn N, Amlish Munir M, Griffiths C, et al. High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic, but not acute, graft-versus-host disease. Biol Blood Marrow Transplant. (2014) 20:1156–62. 10.1016/j.bbmt.2014.04.007
- Schleuning M, Günther W. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant. (2003) 32:243–50. 10.1038/sj.bmt.1704135
- Xie X, Zhao H, Qin D, Qiao X. Pharmacokinetics and pharmacodynamics of two antithymocyte globulins in treatment of pediatric aplastic anemia. Int J Clin Exp Med. (2015) 8:4349–55.
- Storek J. Impact of Serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. Biol Blood Marrow Transplant. (2015) 21:385–6. 10.1016/j.bbmt.2015.01.004
- Bourdage JS, Cook CA, Farrington DL, Chain JS, Konrad RJ. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. (2007) 327:10–7. 10.1016/j.jim.2007.07.004
- Leitner J, Grabmeier-Pfistershammer K, Majdic O, Zlabinger G, Steinberger P. Interaction of antithymocyte globulins with dendritic cell antigens. Am J Transplant. (2011) 11:138–45. 10.1111/j.1600-6143.2010.03322.x
- Breitinger HH, Rojewski MT, Schrezenmeier H. Antibodies to glycosylphosphatidyl-inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: Possible role for the expansion of GPI-AP deficient cells in aplastic anemia. Ann Hematol. (2009) 88:889–95. 10.1007/s00277-008-0688-0
- Elmahdi S, Muramatsu H, Narita A, Torii Y, Ismael O, Kawashima N, et al. . Correlation of rabbit antithymocyte globulin serum levels and clinical outcomes in children who received hematopoietic stem cell transplantation from an alternative donor. Pediatr Transplant. (2016) 20:105–13. 10.1111/petr.12620
- Crocchiolo R, Esterni B, Castagna L, Fürst S, El-Cheikh J, Devillier R, et al. . Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer. (2013) 119:986–92. 10.1002/cncr.27858
- Wang Y, Fu HX, Liu DH, Xu LP, Zhang XH, Chang YJ, et al. . Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant. (2014) 49:426–33. 10.1038/bmt.2013.191
- Duval M, Pédron B, Rohrlich P, Legrand F, Faye A, Lescoeur B, et al. . Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant. (2002) 30:421–6. 10.1038/sj.bmt.1703680
- Devillier R, Crocchiolo R, Castagna L, Fürst S, El Cheikh J, Faucher C, et al. . The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant. (2012) 47:639–45. 10.1038/bmt.2012.3
- Liu J, Xu L-P, Bian Z, Chang Y-J, Wang Y, Zhang X-H, et al. . Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. J Transl Med. (2015) 13:391. 10.1186/s12967-015-0748-x
- Devillier R, Labopin M, Chevallier P, Ledoux M-P, Socié G, Huynh A, et al. . Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of bone marrow. Bone Marrow Transplant. (2018) 53:431–7. 10.1038/s41409-017-0043-y
- Cornillon J, Balsat M, Cabrespine A, Tavernier-Tardy E, Hermet E, Mulliez A, et al. . Impact of ATG dose on the outcome of patients undergoing reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation for hematological malignancies. Acta Haematol. (2016) 136:93–200. 10.1159/000446835
- Chang YJ, Wang Y, Mo XD, Zhang XH, Xu LP, Yan CH, et al. . Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial. Cancer. (2017) 123:2881–92. 10.1002/cncr.30540
- Remberger M, Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant. (2009) 15:996–9. 10.1016/j.bbmt.2009.04.013
- Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, et al. . Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant. (2008) 14:913–9. 10.1016/j.bbmt.2008.05.023
- Binkert L, Medinger M, Halter JP, Heim D, Gerull S, Holbro A, et al. . Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation. Bone Marrow Transplant. (2015) 50:1331–6. 10.1038/bmt.2015.148
- Huang W, Yu L, Cao T, Li Y, Liu Z, Li H, et al. . The efficacy and safety of rabbit anti-thymocyte globulin vs rabbit anti-T-lymphocyte globulin in peripheral blood stem cell transplantation from unrelated donors. Leuk Lymphoma. (2015) 57:355-63. 10.3109/10428194.2015.1045901
- Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, et al. . Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. (2012) 26:582–8. 10.1038/leu.2011.349
Source: PubMed